- Home
- OBE vs CBIO Comparison
OBE vs CBIO Comparison
Compare OBE & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- CBIO
- Stock Information
- Founded
- OBE 1979
- CBIO 2003
- Country
- OBE Canada
- CBIO United States
- Employees
- OBE N/A
- CBIO N/A
- Industry
- OBE Oil & Gas Production
- CBIO
- Sector
- OBE Energy
- CBIO
- Exchange
- OBE Nasdaq
- CBIO Nasdaq
- Market Cap
- OBE 349.1M
- CBIO 308.0M
- IPO Year
- OBE N/A
- CBIO N/A
- Fundamental
- Price
- OBE $5.82
- CBIO $15.74
- Analyst Decision
- OBE Buy
- CBIO Strong Buy
- Analyst Count
- OBE 2
- CBIO 2
- Target Price
- OBE $11.50
- CBIO $25.00
- AVG Volume (30 Days)
- OBE 424.6K
- CBIO 65.5K
- Earning Date
- OBE 08-13-2025
- CBIO 08-23-2025
- Dividend Yield
- OBE N/A
- CBIO N/A
- EPS Growth
- OBE N/A
- CBIO N/A
- EPS
- OBE N/A
- CBIO N/A
- Revenue
- OBE $525,689,636.00
- CBIO N/A
- Revenue This Year
- OBE N/A
- CBIO N/A
- Revenue Next Year
- OBE $8.69
- CBIO N/A
- P/E Ratio
- OBE N/A
- CBIO N/A
- Revenue Growth
- OBE 15.98
- CBIO N/A
- 52 Week Low
- OBE $3.88
- CBIO $11.06
- 52 Week High
- OBE $7.87
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- OBE 65.04
- CBIO N/A
- Support Level
- OBE $5.42
- CBIO N/A
- Resistance Level
- OBE $5.60
- CBIO N/A
- Average True Range (ATR)
- OBE 0.24
- CBIO 0.00
- MACD
- OBE -0.01
- CBIO 0.00
- Stochastic Oscillator
- OBE 81.33
- CBIO 0.00
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.